GeneDx Holdings Corp. (NASDAQ:WGS) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of GeneDx Holdings Corp. (NASDAQ:WGS) have received an average recommendation of “Moderate Buy” from the nine brokerages that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and seven have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $87.4286.

Several equities research analysts have recently weighed in on WGS shares. Wall Street Zen downgraded GeneDx from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Piper Sandler restated an “overweight” rating and set a $63.00 price objective (up from $50.00) on shares of GeneDx in a report on Tuesday, June 23rd. BTIG Research lowered their target price on GeneDx from $170.00 to $90.00 and set a “buy” rating for the company in a report on Tuesday, May 5th. Guggenheim reissued a “buy” rating and set a $74.00 price target (up from $70.00) on shares of GeneDx in a research report on Monday, June 29th. Finally, Zacks Research upgraded GeneDx from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 28th.

GeneDx News Summary

Here are the key news stories impacting GeneDx this week:

• Positive Sentiment: Quarterly results beat estimates: GeneDx reported adjusted EPS of $0.01, above the consensus estimate of a $0.19 loss, while revenue increased 11.4% year over year to $114.4 million, ahead of expectations. GeneDx quarterly earnings report
• Positive Sentiment: Full-year revenue guidance reaffirmed: Management maintained its 2026 revenue forecast of $475 million to $490 million, broadly in line with the $477.1 million analyst consensus. The company expects a meaningful improvement in collection rates beginning in the fourth quarter, which could support future revenue quality and cash generation. GeneDx reaffirms 2026 revenue guidance
• Positive Sentiment: Gross profit increased: Gross profit rose approximately 10% to $78.2 million, indicating that GeneDx continues to expand its top line despite a challenging profitability environment. GeneDx second-quarter financial results
• Neutral Sentiment: Investor positioning is mixed: Recent institutional filings showed both sizable additions and reductions in WGS positions. Reported insider activity was also mixed, with large purchases by certain investors alongside sales by company executives, offering no clear signal about near-term sentiment.
• Negative Sentiment: Profitability and cash flow remain weak: GeneDx posted a $17.5 million operating loss, a $17.7 million net loss, and $29 million in operating cash outflow. Losses worsened from the prior year, while cash stood at $60.3 million and total liabilities reached $237.3 million. GeneDx Q2 losses and cash flow report
• Negative Sentiment: Securities litigation adds risk: Several law firms publicized a class-action lawsuit alleging securities-law violations related to purchases made between April 16, 2025, and May 4, 2026. The allegations are not proven, but the litigation could create financial, reputational, and management risks. GeneDx securities class action announcement

GeneDx Stock Performance

Shares of NASDAQ:WGS opened at $67.86 on Tuesday. The company has a current ratio of 3.09, a quick ratio of 2.95 and a debt-to-equity ratio of 0.38. GeneDx has a 12 month low of $32.21 and a 12 month high of $170.87. The company has a market capitalization of $2.01 billion, a price-to-earnings ratio of -25.32 and a beta of 1.92. The firm’s 50-day moving average is $61.08 and its 200 day moving average is $69.30.

GeneDx (NASDAQ:WGS) last announced its quarterly earnings data on Monday, August 3rd. The company reported $0.01 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.20. GeneDx had a negative net margin of 17.58% and a positive return on equity of 9.15%. The business had revenue of $114.44 million during the quarter, compared to the consensus estimate of $111.01 million. During the same quarter last year, the firm earned $0.36 earnings per share. Research analysts predict that GeneDx will post -1 EPS for the current year.

Insider Transactions at GeneDx

In other GeneDx news, Director Casdin Capital, Llc purchased 185,000 shares of GeneDx stock in a transaction dated Tuesday, May 19th. The stock was acquired at an average price of $42.60 per share, for a total transaction of $7,881,000.00. Following the acquisition, the director owned 3,367,164 shares in the company, valued at $143,441,186.40. This trade represents a 5.81% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Keith A. Meister purchased 533,758 shares of the stock in a transaction dated Thursday, May 7th. The stock was acquired at an average cost of $37.86 per share, with a total value of $20,208,077.88. Following the transaction, the director directly owned 3,761,908 shares in the company, valued at approximately $142,425,836.88. This trade represents a 16.53% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders have acquired 2,256,420 shares of company stock worth $93,144,340 and have sold 19,135 shares worth $1,128,499. Company insiders own 25.17% of the company’s stock.

Institutional Trading of GeneDx

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Kestra Advisory Services LLC purchased a new stake in shares of GeneDx during the 4th quarter worth $27,000. Fifth Third Bancorp bought a new position in GeneDx in the first quarter worth about $31,000. Quarry LP lifted its position in shares of GeneDx by 248.8% during the third quarter. Quarry LP now owns 293 shares of the company’s stock valued at $32,000 after buying an additional 209 shares during the last quarter. Ramirez Asset Management Inc. purchased a new stake in shares of GeneDx during the fourth quarter valued at about $33,000. Finally, Greenline Wealth Management LLC bought a new stake in shares of GeneDx in the 4th quarter valued at about $33,000. Institutional investors own 61.72% of the company’s stock.

GeneDx Company Profile

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.